WaferGen Bio-systems, Inc. (NASDAQ:WGBS) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

As previously reported, at the 2016 Annual Meeting of Stockholders of WaferGen Bio-systems, Inc. (the “Company”) held on May 25, 2016, the holders of a majority of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), approved a proposal to grant discretionary authority to the Board of Directors to amend the Company’s articles of incorporation to effect a reverse stock split of the outstanding shares of Common Stock of the Company, at any time within one year after stockholder approval is obtained, by a ratio of not less than one-for-two and not more than one-for-ten, with the exact ratio to be set at a number within this range as determined by the Board of Directors in its sole discretion.

On November 22, 2016, the Company filed with the Secretary of State of the State of Nevada a certificate of amendment (the “Certificate of Amendment”) to its articles of incorporation, which Certificate of Amendment effectuated as of November 28, 2016 at 4:01 p.m. Pacific Time (the “Effective Time”) the proposed reverse stock split by a ratio of one-for-five (the “Reverse Split”). At the Effective Time, every five outstanding shares of Common Stock became one share of Common Stock.

The Common Stock will commence trading on a split-adjusted basis on the NASDAQ Capital Market when the market opens on November 29, 2016. The trading symbol for the Common Stock will remain “WGBS”. The new CUSIP number for the Common Stock following the Reverse Split is 93041P 506.

No fractional shares were, or shall be, issued in connection with the Reverse Split. A stockholder who would otherwise be entitled to receive a fractional share of Common Stock will be entitled to receive the fractional share rounded up to the next whole share. The Reverse Split did not change the number of shares of common or preferred stock that the Company is authorized to issue, or the par value of the Company’s common or preferred stock.

Item 8.01. Other Events.

On November 28, 2016, the Company issued a press release relating to the reverse split.

Item 9.01. Financial Statements and Exhibits.

The exhibit filed as a part of this Current Report on Form 8-K is listed in the Exhibit Index attached hereto and incorporated herein by reference.

About WaferGen Bio-systems, Inc. (NASDAQ:WGBS)
WaferGen Bio-systems, Inc. (WaferGen) is engaged in the development, manufacture and sale of genomic technology solutions for single-cell analysis (SCA) and clinical research. The Company focuses on marketing an open format genetic analysis system, the WaferGen SmartChip System. The Company’s ICELL8 Single-Cell System is a platform that can isolate a range of single cells and process specific cells for analysis, including Next Generation Sequencing (NGS). ICELL8 is based upon the Company’s SmartChip platform, which is also used for profiling and validating molecular biomarkers. The Company’s SmartChip is a micro-fabricated chip comprising a range of massively-parallel micro wells that are physically separated from each other. It offers SmartChip System Capabilities, SmartChip Single-Cell Isolation System, SmartChip Target Enrichment (TE) System and Apollo 324 Library Preparation. WaferGen Bio-systems, Inc. (NASDAQ:WGBS) Recent Trading Information
WaferGen Bio-systems, Inc. (NASDAQ:WGBS) closed its last trading session down -0.010 at 0.920 with 182,914 shares trading hands.